Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ani Pharmaceuticals (ANIP) Total Non-Current Liabilities: 2011-2025

Historic Total Non-Current Liabilities for Ani Pharmaceuticals (ANIP) over the last 9 years, with Sep 2025 value amounting to $891.0 million.

  • Ani Pharmaceuticals' Total Non-Current Liabilities rose 6.52% to $891.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $891.0 million, marking a year-over-year increase of 6.52%. This contributed to the annual value of $835.3 million for FY2024, which is 97.56% up from last year.
  • Latest data reveals that Ani Pharmaceuticals reported Total Non-Current Liabilities of $891.0 million as of Q3 2025, which was up 3.20% from $863.3 million recorded in Q2 2025.
  • Ani Pharmaceuticals' 5-year Total Non-Current Liabilities high stood at $891.0 million for Q3 2025, and its period low was $251.8 million during Q1 2021.
  • In the last 3 years, Ani Pharmaceuticals' Total Non-Current Liabilities had a median value of $428.2 million in 2024 and averaged $616.8 million.
  • In the last 5 years, Ani Pharmaceuticals' Total Non-Current Liabilities dropped by 5.87% in 2021 and then spiked by 101.59% in 2025.
  • Ani Pharmaceuticals' Total Non-Current Liabilities (Quarterly) stood at $381.9 million in 2021, then rose by 1.21% to $386.5 million in 2022, then grew by 9.40% to $422.8 million in 2023, then surged by 97.56% to $835.3 million in 2024, then climbed by 6.52% to $891.0 million in 2025.
  • Its Total Non-Current Liabilities was $891.0 million in Q3 2025, compared to $863.3 million in Q2 2025 and $831.5 million in Q1 2025.